Gaudium IVF Files Monitoring Agency Report for Q4 FY26, IPO Proceeds Utilization Under Review
Gaudium IVF and Women Health Limited submitted its Monitoring Agency Report for the quarter ended March 31, 2026. The report covers the utilization of IPO proceeds amounting to ₹90.00 crore. During the quarter, ₹8.69 crore was utilized, with ₹0.97 crore for general corporate purposes and ₹7.72 crore for issue expenses. A significant portion of IPO proceeds remains unutilized.
This is a routine monitoring report as per SEBI regulations and does not contain any new material information that would significantly impact the company's stock or investor decisions.
The announcement is a routine regulatory filing regarding IPO proceeds utilization. While it details the financial aspects, there are no significant positive or negative developments reported.
Gaudium IVF and Women Health Limited has submitted its Monitoring Agency Report for the quarter ended March 31, 2026, as required by SEBI regulations. The report, issued by Infomerics Valuation and Rating Limited, details the utilization of proceeds from the company's Initial Public Offer (IPO).
The IPO, which raised ₹90.00 crore, had a net proceeds of ₹82.28 crore available for utilization after deducting issue expenses of ₹7.72 crore. The company's IPO aimed to fund capital expenditure for establishing new IVF centers (₹50.00 crore), repay borrowings (₹20.00 crore), and for general corporate purposes (₹12.28 crore).
During the quarter ended March 31, 2026, the company utilized ₹0.97 crore for general corporate purposes and ₹7.72 crore for issue expenses. A total of ₹8.69 crore was utilized during the quarter. The remaining unutilized amount of ₹81.31 crore is invested in fixed deposits with HDFC Bank and current accounts with HDFC Bank and Axis Bank.
The report indicates that while the company has not utilized proceeds for establishing new IVF centers or repaying borrowings during this specific quarter, the unutilized amounts remain earmarked for the stated objects. The company's management attributes the delay in deployment to commercial and operational considerations, with the Prospectus allowing for utilization in subsequent fiscal periods.
What to do with a filing like this
Gaudium IVF and Women Health Limited filed this with the NSE as a statutory disclosure, categorised under other regulatory filings. It is a primary document, not a recommendation, and the desk marks it low impact, the band that almost never moves a portfolio on its own.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Gaudium IVF and Women Health Limited. Read the original for the full detail.